Navigation Links
Gene Tests Match Up Lung Tumors, Best Treatment
Date:10/3/2007

DNA indicates whether chemo will work, experts say

WEDNESDAY, Oct. 3 (HealthDay News) -- Identifying a lung tumor's genetic profile may help doctors determine the best chemotherapy for patients, U.S. research suggests.

"We were able to predict which tumors would be most likely to respond to standard first-line therapy and which would respond better to what has traditionally been a second-line therapy, based on gene expression profiling," lead author and oncologist Dr. David Hsu, of Duke University in Durham, N.C., said in a prepared statement.

"This represents a big step in the move toward individualized medicine," he said. "This could also make a huge difference in the treatment of patients with late-stage lung cancer, as most of these patients gain the most benefit from their initial treatment strategy."

The findings are published in the Oct. 1 issue of the Journal of Clinical Oncology.

The researchers determined that there are distinct differences in lung tumors' susceptibility to chemotherapy drugs.

In the first part of the study, Hsu's team found that certain genes expressed in non-small cell lung cancer (NSCLC) tumors known to be sensitive to cisplatin (the most commonly-used agent in the treatment of lung cancer) were not expressed in tumors known to be resistant to cisplatin. They also found that genes expressed in the tumors resistant to cisplatin were expressed in tumors sensitive to it.

In the next phase of the research, the team examined a number of second-line therapies for lung cancer, including pemetrexed, which uses a different mechanism of action to fight NSCLC tumors.

"We found the strongest inverse correlation between tumors that were sensitive to cisplatin and those that were sensitive to pemetrexed," senior author and oncologist Dr. Anil Potti said in a prepared statement. "This suggests that some patients who are not likely to respond to cisplatin should perhaps be treated with pemetrexed first."

The findings have formed the basis of a clinical trial -- the first of its kind in lung cancer -- currently being conducted at Duke University.

"These are not experimental drugs; we know they work. It's just a matter of giving each patient the right one on the first try," Potti said.

More information

The American Medical Association has more about lung cancer.



-- Robert Preidt



SOURCE: Duke University, news release, Sept. 28, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. IMA wants members not to do sex determination tests during pregnancy
2. Doctors advice early anemia tests
3. Early diagnosis for autism from blood tests may be possible
4. FDA approves Phase 0 trial which tests experimental drugs on humans
5. Genetic tests for cancer
6. Space research leads to needle-free blood tests
7. The Effectiveness Of Screening Tests Questioned
8. Blood Tests Can Help Detect Osteoporosis Early In Life
9. Easier Tests To Detect Tuberculosis
10. Fragile X-Associated Tremor /Ataxia Syndrome Need Guidelines For Diagnostic Tests
11. Skin tests confirms cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the memo ... Generation Mindful. To help change the mindset of parents and educators from punitive to ... the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that ... its marketing efforts with its product now available through Jet.com. , After 25 ... The effervescent powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... “Our Mountains ... potent tale of a couple that grew stronger together through the faith they shared ... Faith Through Trials” is the creation of published author, Barbara J. Corcoran, a retired ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Beyond Our Imaginations: ... life. “Beyond Our Imaginations: The Infinite God” is the creation of published author, Mark ... the country. , Lawrence shares, “The problem with becoming a greater man of God ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Kingdom Mandate for ... the Kingdom. “Kingdom Mandate for Kingdom Builders” is the creation of published author, ... moved to Eastern Europe as a missionary in 1983. He spent three decades ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
(Date:8/4/2017)... 2017 The search for test results that ... consult has long been the goal of healthcare providers ... of the largest meeting of lab professionals and IVD ... research firm Kalorama Information.  The firm said scores of ... related supplies and software were at the American Association ...
(Date:8/3/2017)...  Opioid addiction and other drugs of abuse, blood ... threatening outcomes, were problems taken on directly as laboratory ... support them, met this week. This according to Kalorama ... of abuse, procalcitonin and acute kidney injury were key ... meeting in San Diego, CA. ...
Breaking Medicine Technology: